Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on March 30, 2018. The filing reports the entry into a material definitive agreement regarding the company's At-The-Market (ATM) equity offering program.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figures disclosed relate to the equity offering program:
- Total ATM Offering Capacity: $150,000,000
- Remaining Shares to be Sold (as of March 30, 2018): $72,581,660
Material Changes
On March 30, 2018, the Company entered into an amendment to its existing Sales Agreement with Cowen and Company, LLC. This amendment allows the Company to continue selling the remaining shares under the ATM Offering. The amendment was executed in connection with a prospectus supplement filed on the same date, relating to the Company's automatically effective Registration Statement on Form S-3 (File No. 333-223123).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose specific risks or contingencies beyond the standard legal references to the validity of the securities issued under the ATM Offering.
Key Facts for Investor Verification
- Verify the current status of the $72,581,660 remaining offering capacity under the amended Sales Agreement with Cowen.
- Review the attached Exhibit 1.1 (Amendment No. 1 to Sales Agreement) for specific terms, fees, and conditions of the amended agreement.
- Confirm the details of the prospectus supplement filed on March 30, 2018, referenced in the filing.
- Note that this filing does not contain updated financial results; refer to the most recent Form 10-Q or 10-K for operational and financial performance data.